Germany’s Merck benefits from efficiency measures, with 2013 EBITDA up 9.7%

6 March 2014

German pharma and chemical major Merck KGaA (MRK: DE) this morning announced strong fourth-quarter and full-year 2013 results and the achievement of its objectives for the year, despite a challenging market environment.

In the fourth quarter of 2013, Merck posted organic sales growth of around 4% compared with the year-earlier quarter. However, this was more than offset by negative foreign exchange effects of around 7%. Consequently, sales in the fourth quarter of 2013 declined to 2.64 billion euros ($3.64 billion), corresponding to a fall of 2.8%. Merck’s shares slipped 0.96% to 123.80 euros in early trading.

Profit in line with expectations

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK